HasenTech

HasenTech is a company headquartered in Leverett, the United States. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.

HasenTech develops cell-based therapy tools using exopolysaccharide from Bacillus subtilis to induce anti-inflammatory myeloid cells that inhibit T cell activation, aiming to prevent and treat graft versus host disease and other inflammatory disorders.